GNH USA

Europe — EMA

Levonorgestrel/Etinilestradiol Diario Durban (Ethinylestradiol, Levonorgestrel | Lactose)

GNH USA supplies Levonorgestrel/Etinilestradiol Diario Durban (Ethinylestradiol/Levonorgestrel), a combined oral contraceptive for pregnancy prevention.

Ethinylestradiol, Levonorgestrel | Lactose

Request sourcing

1
Pack/s

What is Ethinylestradiol, Levonorgestrel | Lactose?

Ethinylestradiol, the active ingredient in Levonorgestrel/Etinilestradiol Diario Durban, is a combined oral contraceptive presented as a tablet for oral use. It is indicated for preventing pregnancy in women of reproductive age. GNH USA supplies Levonorgestrel/Etinilestradiol Diario Durban as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Ethinylestradiol, Levonorgestrel | Lactose used for?

Levonorgestrel/Etinilestradiol Diario Durban, a combined oral contraceptive, is used within the hormonal contraception pathway.

Contraception: Prevents pregnancy by inhibiting ovulation and altering cervical mucus. Menstrual cycle regulation: Helps establish regular menstrual bleeding patterns. Dysmenorrhea management: Reduces the severity of painful menstrual cramps.

What are the side effects of Ethinylestradiol, Levonorgestrel | Lactose?

Levonorgestrel/Etinilestradiol Diario Durban may cause a range of adverse reactions.

Common Side Effects: - Nausea or mild stomach upset. - Breast tenderness or enlargement. - Headache or migraine. - Spotting or breakthrough bleeding. - Mood swings or mild depression. - Weight fluctuation.

Serious or Rare Side Effects: - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. - Severe hypertension or cardiovascular complications. - Liver dysfunction or cholestatic jaundice. - Anaphylactic or severe allergic reactions. - Visual disturbances or ocular migraines. - Gallbladder disease, including cholelithiasis.

What precautions apply to Ethinylestradiol, Levonorgestrel | Lactose?

Before prescribing Levonorgestrel/Etinilestradiol Diario Durban, clinicians should consider several safety aspects.

Medical history review: Assess for clotting disorders, cardiovascular disease, liver disease, and smoking status. Contraindications: Avoid use in known pregnancy, thrombophilia, uncontrolled hypertension, or active liver disease. Drug interaction check: Evaluate concomitant medications that may induce hepatic enzymes or affect coagulation. Monitoring: Periodic blood pressure and lipid profile assessments are recommended. Store at ambient temperature: Keep below 25°C in the original packaging, protect from moisture.

What does Ethinylestradiol, Levonorgestrel | Lactose interact with?

Levonorgestrel/Etinilestradiol Diario Durban can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce contraceptive efficacy. - Concurrent anticoagulants (e.g., warfarin) can increase thrombosis risk. - Certain antiretrovirals (e.g., protease inhibitors) may alter hormone levels.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors may heighten mood‑related side effects. - Antihypertensive agents may require blood‑pressure monitoring when combined. - Herbal supplements such as St. John’s wort can modestly decrease effectiveness.

Frequently asked questions

What is Levonorgestrel/Etinilestradiol Diario Durban used for?+
Levonorgestrel/Etinilestradiol Diario Durban is a combined oral contraceptive tablet used to prevent pregnancy in women of reproductive age. It works by inhibiting ovulation and creating cervical mucus changes that reduce the chance of fertilisation and implantation.
How does Ethinylestradiol work in this product?+
Ethinylestradiol, the estrogen component, stabilises the endometrial lining and contributes to the suppression of the luteinising hormone surge. Together with levonorgestrel, it prevents the release of an egg and modifies cervical mucus, providing effective contraception.
What is the usual dose of Levonorgestrel/Etinilestradiol Diario Durban?+
The specific dosing regimen for Levonorgestrel/Etinilestradiol Diario Durban is determined by the prescribing healthcare professional. The prescriber will select the appropriate tablet strength, frequency and duration based on individual patient needs and clinical guidelines.
Is this medication safe to use during pregnancy or breastfeeding?+
Levonorgestrel/Etinilestradiol Diario Durban is contraindicated during pregnancy because it is intended to prevent conception. Use while breastfeeding should be discussed with a healthcare provider, as hormonal contraceptives may affect milk production and infant exposure.
How do I order Levonorgestrel/Etinilestradiol Diario Durban from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does this product compare with other combined oral contraceptives?+
Levonorgestrel/Etinilestradiol Diario Durban contains the widely used estrogen‑progestogen pair of ethinylestradiol and levonorgestrel, offering a balance of efficacy and tolerability comparable to other second‑generation combined pills. Differences among products typically relate to hormone dose, tablet formulation and specific brand‑related excipients.
What are the recommended storage conditions for this tablet?+
Store Levonorgestrel/Etinilestradiol Diario Durban at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure they are out of reach of children.
How is Levonorgestrel/Etinilestradiol Diario Durban administered?+
The medication is taken orally, usually once daily at the same time each day, as directed by the prescriber. Tablets should be swallowed whole with water and not chewed or broken, unless specific instructions are provided.
What are the most serious risks associated with this contraceptive?+
Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe hypertension, liver disorders, and rare allergic reactions. Patients should seek immediate medical attention if they experience unexplained leg pain, shortness of breath, severe headache, jaundice or signs of an allergic reaction.
Who should not use Levonorgestrel/Etinilestradiol Diario Durban?+
Women with a known history of clotting disorders, active or past thromboembolic disease, uncontrolled hypertension, certain liver diseases, current pregnancy, or those who smoke heavily and are over 35 years old should avoid this product. A thorough medical assessment is essential before initiation.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Ethinylestradiol, Levonorgestrel | Lactose
Route
Oral Use
Manufacturer
Laboratorios Francisco Durbán S.A.
Origin
EU

Related products

Asterluna Continu

Asterluna Continu

Ethinylestradiol, Levonorgestrel | Lactose

Exeltis Healthcare S.L
EU
Asumate

Asumate

Ethinylestradiol, Levonorgestrel | Lactose

Exeltis Czech S.R.O.
EU
Asumate 30/21+7

Asumate 30/21+7

Ethinylestradiol, Levonorgestrel | Lactose

Exeltis Germany Gmbh
EU
Cillia

Cillia

Ethinylestradiol, Levonorgestrel | Lactose

Litcon Pharma Se
EU